{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:40:33Z","timestamp":1792024833645,"version":"4.4.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The LIAISON\u00ae QuantiFERON\u00ae-TB Gold Plus (QFT-Plus) assay, a fully automated chemiluminescence immunoassay (CLIA) system, has recently received FDA approval for the detection of interferon-\u03b3 (IFN-\u03b3) on the LIAISON XL analyzer. Here, we evaluated the diagnostic performance of the LIAISON\u2019s CLIA method in comparison to the widely used ELISA method using the Qiagen QuantiFERON-TB Gold Plus Blood Collection Tubes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Heparinized blood samples from 329 participants were categorized into 3 cohorts, including 15 with confirmed tuberculosis (TB) (active TB cohort), 129 non-TB (low-risk cohort), and 185 potential TB (mixed risk cohort). Samples were analyzed with both assays and results were interpreted according to the manufacturers\u2019 criteria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The LIAISON CLIA assay showed an overall agreement with the Qiagen ELISA assay in 13\/14 (92.8%) samples among the active cohort, 93\/95 (97.9%) among the low-risk cohort, with a Cohen\u2019s kappa value of 0.76 and 0.74, respectively. Test results for 185 mixed risk cohort participants showed 97.8% agreement between the LIAISON and the Qiagen, with 17 positive, 163 negative, and 1 indeterminate. Four samples were discrepant; 3 of these were negative on the ELISA but positive on the CLIA assay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Overall, the results were comparable (&amp;gt;92% agreement) in our study cohorts. In addition, our mixed risk cohort results showed an excellent agreement of 0.88 (Cohen\u2019s kappa value) between the 2 assays. These findings suggest that the automated LIAISON QFT-Plus assay has a comparable diagnostic performance to the Qiagen assay and can be used for latent TB infection (LTBI) diagnosis.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jalm\/jfab012","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T20:14:04Z","timestamp":1614629644000},"page":"1287-1292","source":"Crossref","is-referenced-by-count":21,"title":["Performance of an Advanced Interferon-Gamma Release Assay for<i>Mycobacterium tuberculosis<\/i>Detection"],"prefix":"10.1093","volume":"6","author":[{"given":"Ghaith","family":"Altawallbeh","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Gabrielson","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M","family":"Peters","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony A","family":"Killeen","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"key":"2021090112213080200_jfab012-B1","volume-title":"Reported tuberculosis in the United States, 2018","year":"2019"},{"key":"2021090112213080200_jfab012-B2","author":"Kanabus","year":"2020"},{"key":"2021090112213080200_jfab012-B3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1164\/rccm.201308-1480OC","article-title":"Persistent latent tuberculosis reactivation risk in United States immigrants","volume":"189","author":"Walter","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2021090112213080200_jfab012-B4","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S1473-3099(17)30248-7","article-title":"Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA","volume":"17","author":"LoBue","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2021090112213080200_jfab012-B5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw694","article-title":"Official American Thoracic Society\/Infectious Diseases Society of America\/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children","volume-title":"Clin Infect Dis","author":"Lewinsohn","year":"2017"},{"key":"2021090112213080200_jfab012-B6","first-page":"1192","article-title":"False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?","volume":"10","author":"Farhat","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021090112213080200_jfab012-B7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"2021090112213080200_jfab012-B8","year":"2019"},{"key":"2021090112213080200_jfab012-B9","doi-asserted-by":"crossref","first-page":"e00159","DOI":"10.1128\/JCM.00159-20","article-title":"Evaluation of QuantiFERON-TB Gold Plus on Liaison XL in a low-tuberculosis-incidence setting","volume":"58","author":"De Maertelaere","year":"2020","journal-title":"J Clin Microbiol"},{"key":"2021090112213080200_jfab012-B10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/apm.13025","article-title":"Comparative evaluation of CLIA and EIA for Quantiferon-TB Gold Plus","volume":"128","author":"Brantestig","year":"2020","journal-title":"APMIS"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jalm\/article-pdf\/6\/5\/1287\/40198389\/jfab012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jalm\/article-pdf\/6\/5\/1287\/40198389\/jfab012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T13:29:10Z","timestamp":1671456550000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/article\/6\/5\/1287\/6214617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":10,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,4,7]]},"published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jalm\/jfab012","relation":{},"ISSN":["2576-9456","2475-7241"],"issn-type":[{"value":"2576-9456","type":"print"},{"value":"2475-7241","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2021,4,7]]}}}